2012-07-02 16:35 来源:丁香园 作者:hongfcu
- | +


Journal of Hypertension 2012,30:



1. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, et al.Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens2004; 17:904–910.

2. Messerli FH, Christie B, DeCarvalho JG, Aristimuno GG, Suarez DH,Dreslinski GR,et al. Obesity and essential hypertension. Hemody-namics, intravascular volume, sodium excretion, and plasma rennin activity. Arch Intern Med1981; 141:81–85.

3. Stelfox HT, Ahmed SB, Ribeiro RA, Gettings EM, Pomerantsev E, Schmidt U. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume.Crit Care Med 2006; 34:1243–1246.

4. Strazzullo P, Barba G, Cappuccio FP, Siani A, Trevisan M, Farinaro E, et al.Altered renal sodium handling in men with abdominal adiposity: a link to hypertension. J Hypertens 2001; 19:2157–2164.

5. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syn-drome: causes, consequences and therapeutic implications.Pharma-col Ther 2010; 126:159–172.

6. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens2001; 14 (7 Pt 1): 694–698.

7. Shibao C, Gamboa A, Diedrich A, Ertl AC, Chen KY, Byrne DW,et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension 2007; 49:27–33.

8. Grassi G, Seravalle G, Dell’Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36:538–542.

9. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR,et al. Neural mechanisms in human obesity-related hypertension. J Hyper-tens 1999; 17:1125–1133.

10. Narkiewicz K, van de Borne PJH, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98:772–776.

11. Grassi G, Facchini A, Trevano FQ, Dell’Oro R, Arenare F, Tana F, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 2005; 46:321–325.

12. Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, et al. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension 2010; 56:351–358.

13. Dentali F, Sharma AM, Douketis JD. Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep2005; 7:330–336.

14. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hyperten-sion 2005; 45:356–362.

15. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45:9–14.

16. Hall JE, Da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285:17271–17276.

17. Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympath-etic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999; 84:3686–3695.

18. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, et al. Modulation of blood pressure by central mela-nocortinergic pathways. N Engl J Med 2009; 360:44–52.

19. Vollenweider P, Tappy L, Randin D, Schneiter P, Jequier E, Nicod P, et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 1993; 92:147–154.

20. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21:618–623.

21. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41 (3 Pt 2):625–633.

22. Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney disease: The Framing-ham Heart Study. Hypertension 2011; 58:784–790.

23. Falaschetti E, Hingorani AD, Jones A, Charakida M, Finer N, Whincup P, et al. Adiposity and cardiovascular risk factors in a large contem-porary population of prepubertal children. Eur Heart J 2010; 31:3063–3072.

24. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523–1529.

25. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978; 240:1607–1610.

26. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med2002; 162:1867–1872.

27. Ohnishi H, Saitoh S, Akasaka H, Mitsumata K, Chiba M, Furugen M,et al.Incidence of hypertension in individuals with abdominal obesity in a rural Japanese population: the Tanno and Sobetsu study. Hyper-tens Res 2008; 31:1385–1390.

28. Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J ObesRelat Metab Disord2002; 26:48–57.

29. He J, Klag MJ, Whelton PK, Chen JY, Qian MC, He GQ. Body mass and blood pressure in a lean population in southwestern China. Am JEpidemiol 1994; 139:380–389.

30. Zhang L, Zhang WH, Zhang L, Wang PY. Prevalence of overweight/ obesity and its associations with hypertension, diabetes, dyslipidemia, and metabolic syndrome: a survey in the suburban area of Beijing, 2007. Obes Facts 2011; 4:284–289.

31. Ding J, Visser M, Kritchevsky SB, Nevitt M, Newman A, Sutton-Tyrrell K, et al. The association of regional fat depots with hypertension in older persons of white and African American ethnicity. Am J Hyper-tens 2004; 17:971–976.

32. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framing-ham Heart Study. Circulation 2007; 116:39–48.

33. Liu J, Fox CS, Hickson DA, May WD, Hairston KG, Carr JJ, et al.Impact of abdominal visceral and subcutaneous adipose tissue on cardio-metabolic risk factors: the Jackson Heart Study.J Clin Endocrinol Metab 2010; 95:5419–5426.

34. Tank J, Heusser K, Diedrich A, Hering D, Luft FC, Busjahn A, et al. Influences of gender on the interaction between sympathetic nerve traffic and central adiposity. J Clin Endocrinol Metab 2008; 93:4974– 4978.

35. Weyer C, Pratley RE, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. Hypertension 2000; 36:531–537.

36. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hyperten-sion: The Task Force for the Management of Arterial Hyperten-sion of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). JHypertens 2007; 25:1105–1187.

37. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.Hypertension 2008; 51:1403–1419.

38. Molenaar EA, Hwang SJ, Vasan RS, Grobbee DE, Meigs JB, D’Agostino RB Sr, et al.Burden and rates of treatment and control of cardiovas-cular disease risk factors in obesity: the Framingham Heart Study. Diabetes Care 2008; 31:1367–1372.

39. Bhan V, Yan RT, Leiter LA, Fitchett DH, Langer A, Lonn E, et al. Relation between obesity and the attainment of optimal blood pres-sure and lipid targets in high vascular risk outpatients. Am J Cardiol 2010; 106:1270–1276.

40. Lloyd-Jones DM, Evans JC, Larson MG, O’donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000; 36:594–599.

41. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393–404.

42. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncon-trolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046–1058.

43. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M,et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271–2277.

44. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleepapnea, and aldosterone: theory and therapy.Hypertension 2004; 43:518–524.

45. Bender R, Jockel KH, Trautner C, Spraul M, Berger M. Effect of age on excess mortality in obesity. JAMA 1999; 281:1498–1504.

46. Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med2007; 120:863–870.

47. Wassertheil-Smoller S, Fann C, Allman RM, Black HR, Camel GH, Davis B, et al.Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group.Arch Intern Med2000; 160:494–500.

48. Das SR, Alexander KP, Chen AY, Powell-Wiley TM, Diercks DB, Peterson ED, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2011; 58:2642–2650.

49. Maxwell MH, Waks AU, Schroth PC, Karam M, Dornfeld LP. Error in blood-pressure measurement due to incorrect cuff size in obese patients. Lancet 1982; 2:33–36.

50. O’Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension recommendations for convention-al, ambulatory and home blood pressure measurement.J Hypertens 2003; 21:821–848.

51. Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome subjects. J Hypertens 2011; 29:553–564.

52. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients.N Engl J Med1986; 314:334–339.

53. Haufe S, Utz W, Engeli S, Kast P, Bohnke J, Pofahl M, et al.Left ventricular mass and function with reduced-fat or reduced-carbohydrate hypocaloric diets in overweight and obese subjects. Hypertension 2012; 59:70–75.

54. Straznicky N, Grassi G, Esler M, Lambert G, Dixon J, Lambert E, et al. European Society of Hypertension Working Group on Obesity anti-hypertensive effects of weight loss: myth or reality? J Hypertens 2010;28:637–643.

55. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group.Arch Intern Med1997; 157:657–667.

56. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith-West D, et al.Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001;134:1–11.

57. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992; 267:1213–1220.

58. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42:878–884.

59. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharma-cotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335:1194–1199.

60. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002; 20:2257–2267.

61. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hyper-tens 2002; 20:1873–1878.

62. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmaco-therapy for obesity. N Engl J Med 2005; 353:2111–2120.

63. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, et al.Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 2002; 106:2459–2465.

64. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van GL, Maggioni A, et al.Cardiovascular responses to weight management and sibutr-amine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J2007; 28:2915–2923.

65. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord 2005; 29:509–516.

66. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11:1116–1123.

67. Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther2006; 79:500–508.

68. Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, et al. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab 2007; 92:1560–1563.

69. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med2005; 353:2121–2134.

70. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368:1660–1672.

71. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:761–775.

72. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experi-ence from the RIO-Europe study. Lancet 2005; 365:1389–1397.

73. Ruilope LM, Despres JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, et al.Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 2008; 26:357–367.

74. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in over-weight and obese subjects. N Engl J Med 2010; 363:905–917.

75. Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010; 376:517–523.

76. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.Diabetes Obes Metab 2011 [Epub].

77. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341–1352.

78. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.Int J Obes (Lond) 2011[Epub].

79. Carson JL, Ruddy ME, Duff AE, Holmes NJ, Cody RP, Brolin RE. The effect of gastric bypass surgery on hypertension in morbidly obese patients. Arch Intern Med1994; 154:193–200.

80. Hinojosa MW, Varela JE, Smith BR, Che F, Nguyen NT. Resolution of systemic hypertension after laparoscopic gastric bypass. J Gastrointest Surg 2009; 13:793–797.

81. Hofso D, Nordstrand N, Johnson LK, Karlsen TI, Hager H, Jenssen T, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol 2010; 163:735–745.

82. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357:741–752.

83. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36:20–25.

84. Sjostrom CD, Lystig T, Lindroos AK. Impact of weight change, secular trends and ageing on cardiovascular risk factors: 10-year experiences from the SOS study. Int J Obes (Lond) 2011; 35:1413–1420.

85. Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, Karason K, Wedel H, et al.Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307:56–65.

86. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355:1551–1562.

87. Schmieder RE, Gatzka C, Schachinger H, Schobel H, Ruddel H. Obesity as a determinant for response to antihypertensive treatment. BMJ 1993; 307:537–540.

88. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med2000; 342:905–912.

89. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37:250–254.

90. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227–2236.

91. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, et al. Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart2007; 93:968–973.

92. Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med2011; 124:896–899.

93. Zanchetti A. Hypertension: meta-analyses: first-rank evidence or second-hand information? Nat Rev Cardiol 2011; 8:249–251.

94. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49:1047–1055.

95. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417–2428.

96. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolac-tone therapy in patients with true resistant hypertension. Hyperten-sion 2010; 55:147–152.

97. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009; 27:1493–1501.

98. Parving HH, Brenner BM, McMurray JJ, de ZD, Haffner SM, Solomon SD, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.Nephrol Dial Transplant 2009; 24:1663–1671.

99. Abellan J, Leal M, Hernandez-Menarguez F, Garcia-Galbis JA, Marti-nez-Pastor A, de Vinuesa SG, et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl 2005; S20–S24.

100. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903–1909.

101. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932–934.

102. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose meta-bolism in patients with resistant hypertension: a pilot study.Circu-lation 2011; 123:1940–1946.

103. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55:619–626.

104. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multicenter feasibility study. J Am Coll Cardiol 2010; 56:1254–1258.

105. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al.Baroreflex      activation therapy lowers blood pressure in patients with resistant hypertension: results from   the double-blind, random-ized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;   58:765–773.

分页: [ 1 ]   [ 2 ]   [ 3 ]   [ 4 ]  

编辑: 唐方